# Oncology Institute, Inc. (TOIIW) — capital_raise [completed]
Source: SEC API (secapi.ai) · situation sit_a6e4c86117e05988435a · retrieved 2026-08-11T16:12:44.166Z

## Overview
The Oncology Institute, Inc. operates a network of physician-affiliated oncology practices providing cancer treatment and clinical services.

On July 1, 2026, The Oncology Institute, Inc. entered into a Credit Agreement with Orbimed Opportunities (CA) V LLC as initial lender and administrative agent, providing a $75 million term loan facility that was fully drawn on the closing date. The loan bears interest at the higher of (i) the one-month SOFR rate or (ii) 3.00%, plus an applicable margin of 5.75%, and matures on July 1, 2031. The company used proceeds from the loan, together with cash on hand, to repay in full approximately $86 million in aggregate principal amount of its 4% senior secured convertible notes due 2027. Beginning 36 months after closing, the loan amortizes in quarterly installments equal to 7.5% of the original principal amount, together with a repayment premium and exit fee.

## Terms
- Counterparty: Orbimed Opportunities (CA) V LLC · Deal value: $75.0M · Consideration: cash

## Key dates
- Expected close 2026-07-01 · Completed 2026-07-07

## Timeline
- 2026-07-07 · 8-K (0001079973-26-000934): Oncology Institute secures $75M term loan from Orbimed; matures July 2031 — *The Oncology Institute, Inc. operates a network of physician-affiliated oncology practices providing cancer treatment and clinical services.* On July 1, 2026, The Oncology Institute, Inc. entered into a Credit Agreement with Orbimed Opportunities (CA) V LLC as initial lender and administrative agent, providing a $75 million term loan facility that was fully drawn on the closing date. The loan bears interest at the higher of (i) the one-month SOFR rate or (ii) 3.00%, plus an applicable margin of 5.75%, and matures on July 1, 2031. The company used proceeds from the loan, together with cash on hand, to repay in full approximately $86 million in aggregate principal amount of its 4% senior secured convertible notes due 2027. Beginning 36 months after closing, the loan amortizes in quarterly installments equal to 7.5% of the original principal amount, together with a repayment premium and exit fee.
  https://www.sec.gov/Archives/edgar/data/1799191/0001079973-26-000934.txt

## Citations
- 0001079973-26-000934 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000107997326000934